title: Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships.
abstract: BACKGROUND
  The epidermal growth factor receptor (EGFR) is a member of the ErbB family that is involved in a number of processes responsible for cancer development and progression such as angiogenesis, apoptosis, cell proliferation and metastatic spread. Malfunction in activation of protein tyrosine kinases has been shown to result in uncontrolled cell growth. The EGFR TK domain has been identified as suitable target in cancer therapy and tyrosine kinase inhibitors such as erlotinib have been used for treatment of cancer. Mutations in the region of the EGFR gene encoding the tyrosine kinase (TK) domain causes altered responses to EGFR TK inhibitors (TKI). In this paper we perform molecular dynamics simulations and PCA analysis on wild-type and mutant (T854A) structures to gain insight into the structural changes observed in the target protein upon mutation. We also report two novel inhibitors identified by combined approach of QSAR model development.
  
  
  RESULTS
  The wild-type and mutant structure was observed to be stable for 26 ns and 24 ns respectively. In PCA analysis, the mutant structure proved to be more flexible than wild-type. We developed a 3D-QSAR model using 38 thiazolyl-pyrazoline compounds which was later used for prediction of inhibitory activity of natural compounds of ZINC library. The 3D-QSAR model was proved to be robust by the statistical parameters such as r2 (0.9751), q2(0.9491) and pred_r2(0.9525).
  
  
  CONCLUSIONS
  Analysis of molecular dynamics simulations results indicate stability loss and increased flexibility in the mutant structure. This flexibility results in structural changes which render the mutant protein drug resistant against erlotinib. We report two novel compounds having high predicted inhibitory activity to EGFR TK domain with both wild-type and mutant structure.
authors.forename: Sukriti
authors.initials: S
authors.lastname: Goyal
authors.forename: Salma
authors.initials: S
authors.lastname: Jamal
authors.forename: Asheesh
authors.initials: A
authors.lastname: Shanker
authors.forename: Abhinav
authors.initials: A
authors.lastname: Grover
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000648:ultrastructure; D000069347:Erlotinib Hydrochloride / Q000494:pharmacology; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007529:Isoflavones / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy; D056004:Molecular Dynamics Simulation; D009154:Mutation / Q000235:genetics; D009287:Naphthyridines / Q000494:pharmacology; D025341:Principal Component Analysis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology*; D021281:Quantitative Structure-Activity Relationship
chemical_list: C000606149:7-hydroxy-3-(4-methoxyphenyl)-8-((4-methylpiperazin-1-yl)methyl)-4H-chromen-4-one; D000970:Antineoplastic Agents; D007211:Indoles; D007529:Isoflavones; C000606150:N-(2-(1H-indol-3-yl)ethyl)-2-((8-oxo-8H-benzo(c)indolo(3,2,1-ij)(1,5)naphthyridin-12-yl)oxy)propanamide; D009287:Naphthyridines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors